AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21345766
Drug: Compression treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression treatment alone
Trial: 820708
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of synthetic TRH three times a day, 30 minutes before breast feeding
Trial: 29446785
Drug: Salso-bromo-iodine thermal
RxNorm normalized name: 2-bromo-2-methylpropane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salso-bromo-iodine thermal water solution administered by nasal douche twice/day for 10 days a month for 3 months
Trial: 29446785
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline administered by nasal douche twice/day for 10 days a month for 3 months
Trial: 17413915
Drug: Placebo FICB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo FICB with 0.9% saline and intramuscular injection of 0.1 mg/kg morphine
Trial: 11849632
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (Ortho Evra/Evra)
Trial: 10492057
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg) administered during the ovulatory phase (days 13-16 post-onset of menses)
Trial: 10492057
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg) administered during the luteal phase (days 22-26 post-onset of menses)
Trial: 10492057
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg) administered during the follicular phase (days 2-6 post-onset of menses)
Trial: 28035542
Drug: CZSG (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZSG (12 mg orally, thrice daily)
Trial: 28035542
Drug: KFX (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KFX (10 mL orally, thrice daily)
Trial: 22382664
Drug: low-DEX (loading,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-DEX (loading, 3 μg/kg/h for 10 min; maintenance, 0.2 μg/kg/h for 60 min)
Trial: 22382664
Drug: moderate-DEX (loading,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moderate-DEX (loading, 6 μg/kg/h for 10 min; maintenance, 0.4 μg/kg/h for 60 min)
Trial: 17590198
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone furoate 0.1%
Trial: 15731121
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1%
Trial: 9618736
Drug: Cotrimoxazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (100 mg/kg b.w./24 h)
Trial: 2116316
Drug: Almitrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (100 mg oral)
Trial: 6995131
Drug: Clofibate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate 0.5 g
Trial: 6995131
Drug: Bezafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 0.2 g
Trial: 20021927
Drug: tirofiban (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban (intravenous bolus 10 microg/kg followed by intravenous infusion of 0.15 microg/kg/min for 48 h)
Trial: 9871425
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg quinidine premedication
Trial: 7608829
Drug: L. casei
RxNorm normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. casei subsp. rhamnosus (Lactophilus)
Trial: 7608829
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Streptococcus thermophilus and L. delbrückii subsp. bulgaricus (Yalacta)
Trial: 2571860
Drug: CD45 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD45 monoclonal antibodies (mAbs) perfusion
Trial: 2571860
Drug: Control human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control human albumin solution
Trial: 371293
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera chemical vaccine (2 tablets)
Trial: 371293
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera chemical vaccine (3 tablets)
Trial: 31434149
Drug: six-dose IV-TXA
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: six-dose IV-TXA (total dosage more than 6 g)
Trial: 22507386
Drug: Bifidobacterium bifidum
RxNorm normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium bifidum OLB6378 (B. bifidum) administered within 48 hours of birth
Trial: 22507386
Drug: Bifidobacterium bifidum
RxNorm normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium bifidum OLB6378 (B. bifidum) administered more than 48 hours after birth
Trial: 20674669
Drug: Biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agents for treatment of rheumatic diseases
Trial: 17659971
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% every 10 minutes for one hour before surgery
Trial: 17659971
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% every 10 minutes for one hour before surgery
Trial: 10201739
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids pretreatment
Trial: 2118853
Drug: rt-PA 100
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA 100 mg (29.6-48.2 MU) administered over 90 min followed by intravenous heparin
Trial: 30382900
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without 3D image fusion guidance
Trial: 20074202
Drug: Adherence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence therapy intervention
Trial: 20074202
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management training for mental health nurses
Trial: 17342036
Drug: Dobutamine stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine stress echocardiography in small-size AVR group (n=17) with prosthetic aortic valves 21 mm; Peak pressure gradient at rest: 42.1 mm Hg, after dobutamine infusion: 85.1 mm Hg (P<0.05). Isovolumetric relaxation time returned to normal, significant decrease in left atrium and left ventricular diameters and volumes, LVMI decreased from 127.6±47.6 to 98.1±36.9.
Trial: 17342036
Drug: Dobutamine stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine stress echocardiography in large-size AVR group (n=13) with valves >21 mm; Peak pressure gradient at rest: 20.9 mm Hg, after dobutamine infusion: 54 mm Hg (P<0.05). LVMI decreased from 159.9±16.1 to 125.3±10.1.
Trial: 11547472
Drug: Intrathecal 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.3 mg morphine plus intravenous saline (group 1)
Trial: 11547472
Drug: Intravenous 0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.09 mg buprenorphine plus intrathecal saline (group 2)
Trial: 11547472
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.3 mg plus intravenous buprenorphine 0.09 mg (group 3)
Trial: 3045264
Drug: Melphalan (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan (arm B) 8 mg/m2/d X 4 every 4 weeks X 18 courses (106 patients)
Trial: 29079949
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (Control, n=53)
Trial: 19738125
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/d) with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Trial: 19738125
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Trial: 15019365
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 4 mg of triamcinolone acetonide
Trial: 11082826
Drug: 0‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0‐mg nicotine gum (placebo)
Trial: 2453596
Drug: Pyrazinamide (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide (1500 mg for 2 months)
Trial: 26872868
Drug: Traditional protocol
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional protocol (iopromide 370 mg/mL + 120 kV)
Trial: 26872868
Drug: Low tube
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tube voltage (100 kV), low contrast agent concentration (270 mg/mL), and iterative reconstruction
Trial: 24330619
Drug: Cranberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry beverage (450 ml daily for 10 weeks)
Trial: 16361302
Drug: Gabapentin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1.2 g day(‐1))
Trial: 320830
Drug: Pipamperone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipamperone (80 mg daily)
Trial: 7151088
Drug: Intravenous tiapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min infusion for 15 min)
Trial: 7151088
Drug: Intravenous tiapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tiapamil (1.5 mg/kg loading dose followed by 75 micrograms/kg/min infusion for 15 min)
Trial: 27102891
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes before a meal
Trial: 27102891
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes after a meal
Trial: 22260713
Drug: Running therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running therapy (RT) or Nordic walking (NW) in addition to usual care, group-based, 1 hour session, two times a week for 6 months, increasing intensity.
Trial: 17983307
Drug: Daily event
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily event sampling study; Study 3
Trial: 9817265
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone)
Trial: 9817265
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (observation group)
Trial: 9817265
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (for patients with large tumors, both ER+ and ER-)
Trial: 9817265
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (observation group for patients with large tumors, both ER+ and ER-)
Trial: 9817265
Drug: Low-risk patients
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk patients (ER+ tumors < 3 cm) monitored without therapy
Trial: 2664631
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 12 interrupted 10‐0 sutures with a single running 11‐0 suture (IR)
Trial: 765528
Drug: Metaproterenol syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol syrup
Trial: 25452437
Drug: Exercise (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week)
Trial: 11848115
Drug: Auditory, tactile,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory, tactile, visual, and vestibular intervention (ATVV) administered for 15 minutes, twice daily, 5 days per week, from 33 weeks of age until discharge.
Trial: 8597883
Drug: Indomethacin, diclofenac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, diclofenac, and naproxen (nonsteroidal anti-inflammatory drugs)
Trial: 2693074
Drug: maprotiline 75
RxNorm normalized name: maprotiline 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline 75 mg
Trial: 2693074
Drug: maprotiline 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline 37.5 mg (1/2 tablet)
Trial: 2693074
Drug: placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 tablet
Trial: 2693074
Drug: placebo 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 37.5 mg (1/2 tablet)
Trial: 352195
Drug: RO 21‐3981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 21‐3981 0.15 mg/kg
Trial: 30885233
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antidepressants
Trial: 30885233
Drug: HDL-cholesterol levels
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL-cholesterol levels (per mmol/l)
Trial: 26747218
Drug: Bag-valve-mask +
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bag-valve-mask + nasal cannula at 10 L/min
Trial: 26747218
Drug: Nonrebreather face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonrebreather face mask + nasal cannula at 10 L/min
Trial: 23156974
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg/kg)
Trial: 23156974
Drug: Flumazenil (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.05 mg/kg)
Trial: 19528136
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (2 years of one agent followed by 3 years of the other)
Trial: 17340069
Drug: Wobe-Mugos E
RxNorm normalized name: pine needle oil (pinus mugo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wobe-Mugos E (proteolytic enzymes) comprising papain 100 mg, trypsin 40 mg, and chymotrypsin 40 mg
Trial: 15206666
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) low-dose isradipine (15 mg)
Trial: 15206666
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) high-dose isradipine (30 mg)
Trial: 15206666
Drug: Low-dose cocaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cocaine HCl (0.325 mg/kg)
Trial: 15206666
Drug: High-dose cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cocaine HCl (0.650 mg/kg)
Trial: 3117399
Drug: Sequential instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential instillation of mitomycin C (MMC) and adriamycin (ADM); 20 mg MMC on day 1 and 40 mg ADM on day 2, repeated weekly for 5 weeks.
Trial: 3117399
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) medication
Trial: 26347218
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (ALA) treatment (600mg once daily)
Trial: 22822623
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa capsules (500 +/- 10 mg per capsule, 2 g per day for 4 weeks)
Trial: 18441041
Drug: Sensorimotor training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensorimotor training programme using a sling suspension system
Trial: 18441041
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy (Control)
Trial: 12556017
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml paper disposable cup
Trial: 3158187
Drug: Diltiazem, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 90 mg three times a day by mouth for 3 months after PTCA
Trial: 3158187
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists discontinued immediately after PTCA (Control)
Trial: 29996492
Drug: IF 1
RxNorm normalized name: SAIF 1 Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF 1 (1.0 g protein/dL)
Trial: 29996492
Drug: IF 2
RxNorm normalized name: GILOTRIF 20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF 2 (1.3 g protein/dL)
Trial: 29996492
Drug: IF 3
RxNorm normalized name: GILOTRIF 30mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF 3 (1.5 g protein/dL)
Trial: 26201313
Drug: Weekly adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly adalimumab
Trial: 26337327
Drug: Clinician feedback
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician feedback group (received feedback weekly)
Trial: 18215618
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (substrates of ABCB1)
Trial: 16377916
Drug: Nasal nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nasal nocturnal oxygen therapy (HOT group, n=25)
Trial: 14651540
Drug: Tolmetin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolmetin (25 mg/kg per day)
Trial: 14651540
Drug: Aspirin (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75-100 mg/kg per day)
Trial: 8972376
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation during surgery
Trial: 8972376
Drug: Air inhalation
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air inhalation during surgery
Trial: 1592575
Drug: Selegiline (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (a selective MAO-B inhibitor)
Trial: 6375274
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg/ml
Trial: 6375274
Drug: Nicomorphine 10
RxNorm normalized name: apomorphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicomorphine 10 mg/ml
Trial: 6375274
Drug: Pethidine 75
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 75 mg/ml
Trial: 30664050
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial direct current stimulation with methadone maintenance treatment
Trial: 30664050
Drug: Sham transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transcranial direct current stimulation with methadone maintenance treatment
Trial: 30664050
Drug: Only methadone
RxNorm normalized name: Product containing only methadone (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only methadone maintenance treatment
Trial: 22340283
Drug: AZD9773 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9773 (50 or 250 units/kg single doses; multiple doses of 250 units/kg loading and 50 units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/kg maintenance)
Trial: 19877169
Drug: Rosiglitazone (RSG),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG), 8 mg/day for 2 years
Trial: 19877169
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) for 2 additional years after initial treatment
Trial: 12105140
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/d)
Trial: 10420109
Drug: Tobramycin 0.3%
RxNorm normalized name: TOBRAMYCIN 0.3% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3% eye drops 4 times daily
Trial: 1341875
Drug: Captopril associated
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril associated with conventional treatment (digitalis and diuretic)
Trial: 1341875
Drug: Captopril associated
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril associated with digitalis or diuretic
Trial: 1341875
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (digitalis and diuretic)
Trial: 6659641
Drug: Penbutolol (negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (negative inotropic agent)
Trial: 6659641
Drug: AR‐L 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR‐L 115 BS (positive inotropic drug)
Trial: 30924348
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antineutrophil cytoplasm autoantibody testing and the European Medicines Agency algorithm
Trial: 29378016
Drug: ASP9226 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP9226 (30 mg)